Trials / Terminated
TerminatedNCT03113071
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
A Phase Ib/II Study of the Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Fox Chase Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | Decitabine will be administered in combination with Digoxin |
| DRUG | Digoxin | Decitabine will be administered in combination with Digoxin |
Timeline
- Start date
- 2017-06-02
- Primary completion
- 2019-01-08
- Completion
- 2019-03-11
- First posted
- 2017-04-13
- Last updated
- 2021-03-16
- Results posted
- 2021-03-16
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03113071. Inclusion in this directory is not an endorsement.